DB17626InvestigationalGene Therapies
ARO-ANG3 is a subcutaneously administered RNA interference (RNAi)-based investigational medicine targeting angiopoietin-like protein 3 (ANGPTL3). It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia (HoFH).
- Mechanism
- Curator reviewed
Pharmacologically active on Angiopoietin-related protein 3
- Also known as
- ARO-ANG3
- Code names
- VSA003
Resolves to
Compound
Targets
What you can answer from here — as of October 05, 2026
Which drugs share a target with Zodasiran, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account